All In Biotech

Drug Trial Radar · NCT05890352

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

227

Planned (sponsor's estimate)

Start

Sep 26, 2023

Primary completion

Dec 1, 2029

Study completion Dec 2029

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); BeiGene; Ipsen; Incyte Corporation
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.

Conditions

  • Grade 3b Follicular Lymphoma
  • High Grade B-Cell Lymphoma
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Transformed Non-Hodgkin Lymphoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo optional collection of blood

  • Computed TomographyProcedure

    Undergo PET/CT and CT

  • LenalidomideDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • TafasitamabBiological

    Given IV

  • TazemetostatDrug

    Given PO

  • ZanubrutinibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
  2. Trial Outcome Index (TOI) score from the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) (Patient Reported Outcome [PRO] Study)Time frame: Baseline up to 3 months after randomization

Locations

104 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • City of Hope Seacliff

    Huntington Beach, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • City of Hope at Long Beach Elm

    Long Beach, California · Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • City of Hope Newport Beach

    Newport Beach, California · Recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Recruiting

  • City of Hope South Bay

    Torrance, California · Recruiting

  • City of Hope Upland

    Upland, California · Recruiting

  • Holy Cross Hospital

    Fort Lauderdale, Florida · Recruiting

  • Mount Sinai Medical Center

    Miami Beach, Florida · Suspended

  • University of Illinois

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Recruiting

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois · Recruiting

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois · Recruiting

  • Memorial Hospital East

    Shiloh, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Northwest Cancer Center - Main Campus

    Crown Point, Indiana · Recruiting

  • Northwest Oncology LLC

    Dyer, Indiana · Recruiting

  • Northwest Cancer Center - Hobart

    Hobart, Indiana · Recruiting

  • Saint Mary Medical Center

    Hobart, Indiana · Recruiting

  • Saint Catherine Hospital

    Indianapolis, Indiana · Recruiting

  • The Community Hospital

    Munster, Indiana · Recruiting

  • Women's Diagnostic Center - Munster

    Munster, Indiana · Recruiting

  • Northwest Cancer Center - Valparaiso

    Valparaiso, Indiana · Recruiting

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa · Suspended

  • Mercy Hospital

    Cedar Rapids, Iowa · Recruiting

  • Oncology Associates at Mercy Medical Center

    Cedar Rapids, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    Clive, Iowa · Suspended

  • Mercy Medical Center - Des Moines

    Des Moines, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Laurel Clinic

    Des Moines, Iowa · Suspended

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor

    Ann Arbor, Michigan · Recruiting

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    Brighton, Michigan · Recruiting

  • Trinity Health Medical Center - Brighton

    Brighton, Michigan · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.